Welcome to our dedicated page for Longeveron SEC filings (Ticker: LGVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Longeveron Inc. filings document a clinical-stage biotechnology issuer developing laromestrocel, an investigational allogeneic cellular therapy, and its related regulatory, financing, governance, and listing disclosures. Form 8-K reports cover FDA communications, clinical-development updates, material agreements, executive and board compensation matters, shareholder meeting actions, and Nasdaq continued-listing notices.
Registration statements and event reports also identify LGVN’s Class A common stock, Nasdaq Capital Market listing, emerging growth company status, and financing-related securities disclosures. The filing record ties the company’s public-company reporting to clinical and regulatory development of laromestrocel, stockholder voting matters, and capital resources used to fund biotechnology operations.
Longeveron Inc. describes changes to executive and director compensation tied to a prior cost-cutting plan. Earlier in 2026, the company temporarily reduced pay for its executive team and Board by about 25% to 50% while reviewing its cash runway and cost structure.
After closing a financing transaction reported on March 12, 2026, and determining it had the financial capacity, Longeveron repaid executives and directors the difference between their original and reduced compensation for the reduction period. In addition, the Compensation Committee approved equity awards of 250,000 restricted stock units for each executive other than the Executive Chairman and 500,000 restricted stock units for the Chief Executive Officer. These RSUs are to be granted on May 1, 2026 and vest quarterly over three years starting July 1, 2026 under the company’s Third Amended and Restated 2021 Incentive Award Plan.
Longeveron Inc. is registering 30,865,385 shares of Class A common stock for resale by existing investors, including shares already issued, shares issuable from preferred stock conversion, and shares underlying placement agent warrants. The company will not receive proceeds from these resales, but could receive up to $1.31 million if all placement agent warrants are exercised in cash.
Longeveron is a clinical-stage biotech focused on its cell therapy candidate laromestrocel (Lomecel-B®) for rare pediatric heart disease (HLHS), Alzheimer’s disease, pediatric dilated cardiomyopathy and aging-related frailty. The filing highlights a recent $15.9 million private placement, substantial doubt about the company’s ability to continue as a going concern, and Nasdaq minimum bid-price noncompliance that could lead to a reverse split or potential delisting if not cured.
Longeveron Inc. General Counsel and Secretary Paul T. Lehr reported a routine tax-related share disposition. On the vesting of a restricted stock unit award, 5,611 shares of Class A common stock were withheld at $1.12 per share to satisfy tax obligations.
Following this tax-withholding event, Lehr directly holds 338,566 shares of Class A common stock, which the disclosure notes includes restricted stock units that are subject to future vesting.
Longeveron Inc. Chief Medical Officer Nataliya Agafonova reported a routine tax-related share disposition. On the vesting of a restricted stock unit award, 13,145 shares of Class A common stock were withheld at $1.12 per share to satisfy tax obligations, rather than sold in the open market.
After this withholding, she directly holds 203,419 shares of Class A common stock, which includes RSUs that are still subject to future vesting. The filing reflects compensation-related share vesting mechanics, not an active decision to buy or sell shares.
Longeveron Inc. Chief Financial Officer Lisa Locklear reported a routine tax-related share disposition. On April 1, 2026, 13,145 shares of Class A Common Stock were withheld at $1.12 per share to satisfy tax obligations tied to vesting of a restricted stock unit award.
After this withholding, Locklear directly holds 215,686 shares of Class A Common Stock, which the disclosure states includes RSUs that are still subject to future vesting. The filing does not show any open-market buying or selling activity.
Longeveron Inc. Chief Executive Officer Willard Stephen H reported a routine tax-related share transaction. On the vesting of a restricted stock unit (RSU) award, 4,740 shares of Class A Common Stock were withheld at $1.12 per share to satisfy tax obligations, rather than being sold in the open market.
Following this tax-withholding disposition, he directly holds 289,727 shares of Class A Common Stock, which includes RSUs subject to future vesting.
Longeveron Inc. executive Devin Blass, CTO & SVP of CMC, reported a routine share disposition related to taxes rather than an open-market trade. On the vesting of a restricted stock unit award, 8,633 shares of Class A Common Stock were withheld at $1.12 per share to satisfy tax obligations. After this tax-withholding event, Blass directly holds 191,543 shares of Class A Common Stock, including RSUs that remain subject to future vesting.
Longeveron Inc. received an additional 180-day period from Nasdaq, until September 21, 2026, to regain compliance with the $1.00 minimum bid price requirement for its Class A common stock. The company remains listed on The Nasdaq Capital Market while it works to restore compliance.
If the closing bid price reaches at least $1.00 per share for ten consecutive business days within this period, Nasdaq can confirm that the requirement has been met. Longeveron plans to monitor its stock price and may use options such as a reverse stock split, but there is no assurance it will satisfy Nasdaq’s listing standards.
Longeveron Inc. cancelled its special meeting of stockholders that had been scheduled for 2026. The company now intends for the previously planned Reverse Stock Split proposal from its March 3, 2026 preliminary proxy statement to be presented instead at its next regularly scheduled annual meeting if it determines this is necessary or advisable.
The filing also includes standard cautionary language that forward-looking statements are subject to risks and uncertainties described in Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2025 and other SEC reports, and notes the company has no obligation to update such statements except as required by law.
Longeveron Inc. is a clinical-stage biotech focused on regenerative cell therapies built around its lead product, laromestrocel (Lomecel‑B), an allogeneic bone‑marrow–derived mesenchymal stem cell therapy. The company is developing laromestrocel for four indications: Hypoplastic Left Heart Syndrome (HLHS), mild Alzheimer’s disease, pediatric dilated cardiomyopathy, and aging‑related frailty.
For HLHS, laromestrocel has Rare Pediatric Disease, Orphan Drug, and Fast Track designations, and the pivotal Phase 2b ELPIS II trial is fully enrolled with top‑line data expected in the third quarter of 2026. For mild Alzheimer’s, a Phase 2a trial (CLEAR MIND) showed a favorable safety profile and signals of efficacy, leading to RMAT and Fast Track designations and FDA alignment on a planned pivotal seamless Phase 2/3 design, with the possibility of a BLA based on positive interim data.
The company operates a cGMP facility in Miami for early‑phase supply but plans to use a contract development and manufacturing organization for potential commercial production, and it has built an extensive global patent and trademark portfolio around laromestrocel and its manufacturing and potency assays.